Evoke+ (H-0249)
Description
Content
This research study will test the effectiveness of an oral medication, semaglutide, in slowing cognitive decline in people with early Alzheimer’s disease. Basic eligibility criteria:
- Ages 55-85
- Diagnosis of amnestic MCI or early AD
- No serious medical conditions that would limit study participation
- Has a study partner who can accompany the participant to most study visits
Contact
Phone 1: 713–798–5325
IRB: H-0249
Status:
Active
Created:
